Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Therapeutic advances using targeted biologicals and small-molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune, and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell–based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic, or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in nononcological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in nononcological settings such as cardiovascular disease, obesity, and chronic inflammatory disorders. After describing the general features of T cell–based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell–based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

Detaljer

Författare
  • Franziska Roth-Walter
  • Ian M. Adcock
  • Cristina Benito-Villalvilla
  • Rodolfo Bianchini
  • Leif Bjermer
  • Onur Boyman
  • Gaetano Caramori
  • Luigi Cari
  • Kian Fan Chung
  • Zuzana Diamant
  • Ibon Eguiluz-Gracia
  • Edward F. Knol
  • Antonios Kolios
  • Francesca Levi-Schaffer
  • Giuseppe Nocentini
  • Oscar Palomares
  • Frank Redegeld
  • Betty Van Esch
  • Cristiana Stellato
Enheter & grupper
Externa organisationer
  • University of Veterinary Medicine Vienna
  • Imperial College London
  • Complutense University of Madrid
  • University Hospital of Zurich
  • University of Messina
  • University of Perugia
  • Royal Brompton and Harefield NHS Foundation Trust
  • Skåne University Hospital
  • Charles University in Prague
  • University Medical Center Groningen
  • Thomayer Hospital
  • University of Groningen
  • Hospital Regional de Málaga
  • University Medical Center Utrecht
  • Hebrew University of Jerusalem
  • Utrecht University
  • University of Salerno
  • University of Zurich
  • QPS-Netherlands
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Lungmedicin och allergi
  • Immunologi inom det medicinska området

Nyckelord

Originalspråkengelska
Sidor (från-till)90-113
Antal sidor24
TidskriftAllergy: European Journal of Allergy and Clinical Immunology
Volym76
Utgåva nummer1
StatusPublished - 2021
PublikationskategoriForskning
Peer review utfördJa